Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human FLT3 ELISA Kit for Sandwich ELISA - ABIN416723
Feng, Xu, Zhou, Wang, Liu, Wu, Yuan, Che: Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress. in Frontiers in physiology 2016
Tumor necrosis factor (TNF (show TNF ELISA Kits)), a cell-extrinsic potent negative regulator of hematopoietic stem cells (HSCs), was overexpressed in bone marrow niche cells from FLT3 internal tandem duplications (FLT3 ITDs) mice.
the angiogenic factor (show VEGFA ELISA Kits) Egfl7 (show EGFL7 ELISA Kits) activates the Flt3/Flt3 ligand (show FLT3LG ELISA Kits) pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity
the Hoxa9 (show HOXA9 ELISA Kits)- and Meis1 (show MEIS1 ELISA Kits)-associated upregulation of Flt3 is a passive event with regard to leukemia development in mice and with limited relevance to the AML (show RUNX1 ELISA Kits) pathology.
lineage-specific STAT5 (show STAT5A ELISA Kits) activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype in mice
DOCK2 (show DOCK2 ELISA Kits) is a potential therapeutic target for novel AML (show RUNX1 ELISA Kits) treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents.
Used a genetic model to determine whether miR (show MLXIP ELISA Kits)-155 influences the development of FLT3-ITD-induced myeloproliferative disease. miR (show MLXIP ELISA Kits)-155 promotes FLT3-ITD-induced myeloid expansion in the bone marrow, spleen, and peripheral blood. Mechanistically, miR (show MLXIP ELISA Kits)-155 increases proliferation of the hematopoietic stem and progenitor cell compartments by reducing the growth-inhibitory effects of the interferon (show IFNA ELISA Kits) response.
Overexpression of Abl (show ABL1 ELISA Kits)-related gene tyrosine kinase (show TYRO3 ELISA Kits) ABL2 in pro-B cell line Ba/F3 cells expressing an oncogenic mutant of FLT3 (FLT3-ITD) resulted in partial inhibition of FLT3-ITD-dependent cell proliferation.
Sorafenib-resistant leukemia cells with a FLT3/ITD mutation are sensitive to glycolytic inhibitors.
FLT3-ITD is capable of inhibiting FLT3-ITD+ cell proliferation through the p21/Pbx1 (show PBX1 ELISA Kits) axis
Data indicate that most Fms-like tyrosine kinase-3 (FLT3) tyrosine kinase (show TYRO3 ELISA Kits) inhibitors (TKI) effectively target wild-type FLT3 signaling.
FLT3/ITD increases aerobic glycolysis through AKT (show AKT1 ELISA Kits)-mediated upregulation of mitochondrial hexokinase (HK2 (show HK2 ELISA Kits)). Inhibition of glycolysis preferentially causes severe ATP depletion and massive cell death in FLT3/ITD leukemia cells.
Our results indicate that CD4 (show CD4 ELISA Kits) expression and older age are adverse prognostic factors in wild-type NPM1 (show NPM1 ELISA Kits), FLT3-ITD-negative CN-AML (show RUNX1 ELISA Kits).
FLT3 mutation is associated with Metaplastic Breast Cancer.
Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L (show FLT3LG ELISA Kits)-guided miR (show MLXIP ELISA Kits)-150-based nanoparticles, to treat FLT3-overexpressing AML (show RUNX1 ELISA Kits) with high efficacy and minimal side effects.
Y842 is critical for FLT3-mediated RAS/ERK (show EPHB2 ELISA Kits) signaling and cellular transformation.
value of FLT3-ITD allelic ratio in AML (show RUNX1 ELISA Kits) in risk assessment and evaluating prognosis
Gedatolisib significantly extended survival of mice in a sorafenib-resistant acute myeloid leukemia (show BCL11A ELISA Kits) (AML (show RUNX1 ELISA Kits)) patient-derived xenograft model. Taken together, our data suggest that aberrant activation of the PI3K (show PIK3CA ELISA Kits)/mTOR (show FRAP1 ELISA Kits) pathway in FLT3-ITD-dependent AML (show RUNX1 ELISA Kits) results in resistance to drugs targeting FLT3.
HHEX (show HHEX ELISA Kits) could replace RUNX1 (show RUNX1 ELISA Kits) in cooperating with FLT3-ITD to induce Acute myeloid leukemia (show BCL11A ELISA Kits) (AML (show RUNX1 ELISA Kits)).
mutated FLT3-ITD and JAK2 (show JAK2 ELISA Kits) augment reactive oxygen species production and homologous recombination, shifting the cellular milieu toward illegitimate recombination.
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
fms-related tyrosine kinase 3
, FL cytokine receptor-like
, FL cytokine receptor
, fetal liver kinase 2
, receptor-type tyrosine-protein kinase FLT3
, tyrosine-protein kinase FLT3
, tyrosine-protein kinase receptor flk-2
, CD135 antigen
, fms-like tyrosine kinase 3
, growth factor receptor tyrosine kinase type III
, stem cell tyrosine kinase 1
, FMS-like tyrosine kinase 3